351 related articles for article (PubMed ID: 12465750)
21. Chemoprevention of prostate cancer: agents and study designs.
Thompson IM
J Urol; 2007 Sep; 178(3 Pt 2):S9-S13. PubMed ID: 17644117
[TBL] [Abstract][Full Text] [Related]
22. Micronutrients in cancer chemoprevention.
Greenwald P; Milner JA; Anderson DE; McDonald SS
Cancer Metastasis Rev; 2002; 21(3-4):217-30. PubMed ID: 12549762
[TBL] [Abstract][Full Text] [Related]
23. Chemoprevention of prostate cancer.
Klein EA
Crit Rev Oncol Hematol; 2005 Apr; 54(1):1-10. PubMed ID: 15780904
[TBL] [Abstract][Full Text] [Related]
24. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
25. Prevention of prostate cancer.
DePrimo SE; Shinghal R; Vidanes G; Brooks JD
Hematol Oncol Clin North Am; 2001 Jun; 15(3):445-57. PubMed ID: 11525290
[TBL] [Abstract][Full Text] [Related]
26. SELECT: the selenium and vitamin E cancer prevention trial.
Klein EA; Thompson IM; Lippman SM; Goodman PJ; Albanes D; Taylor PR; Coltman C
Urol Oncol; 2003; 21(1):59-65. PubMed ID: 12684129
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer prevention: agent development strategies.
Parnes HL; House MG; Tangrea JA
Recent Results Cancer Res; 2014; 202():121-31. PubMed ID: 24531786
[TBL] [Abstract][Full Text] [Related]
28. Use of transgenic mice as models for prostate cancer chemoprevention.
Nguewa PA; Calvo A
Curr Mol Med; 2010 Nov; 10(8):705-18. PubMed ID: 20937024
[TBL] [Abstract][Full Text] [Related]
29. An update on chemoprevention strategies in prostate cancer for 2006.
Neill MG; Fleshner NE
Curr Opin Urol; 2006 May; 16(3):132-7. PubMed ID: 16679848
[TBL] [Abstract][Full Text] [Related]
30. Update on chemoprevention of prostate cancer.
Klein EA; Thompson IM
Curr Opin Urol; 2004 May; 14(3):143-9. PubMed ID: 15069304
[TBL] [Abstract][Full Text] [Related]
31. Chemoprevention in prostate cancer.
Assikis V; Brawley OW
Curr Probl Cancer; 2004; 28(4):218-30. PubMed ID: 15318324
[No Abstract] [Full Text] [Related]
32. Introductory remarks: development of chemopreventive agents for prostate cancer.
Kelloff GJ; Boone CW; Malone WF; Steele VE; Doody LA
J Cell Biochem Suppl; 1992; 16H():1-8. PubMed ID: 1289663
[TBL] [Abstract][Full Text] [Related]
33. Nutraceuticals for prostate cancer chemoprevention: from molecular mechanisms to clinical application.
Wang Z; Fan J; Liu M; Yeung S; Chang A; Chow MS; Pon D; Huang Y
Expert Opin Investig Drugs; 2013 Dec; 22(12):1613-26. PubMed ID: 24050482
[TBL] [Abstract][Full Text] [Related]
34. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
[TBL] [Abstract][Full Text] [Related]
35. Chemoprevention of prostate cancer: an updated view.
Klein EA; Thompson IM
World J Urol; 2012 Apr; 30(2):189-94. PubMed ID: 22238120
[TBL] [Abstract][Full Text] [Related]
36. Selective estrogen receptor modulators for the chemoprevention of prostate cancer.
Steiner MS; Raghow S; Neubauer BL
Urology; 2001 Apr; 57(4 Suppl 1):68-72. PubMed ID: 11295598
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer chemoprevention: an overview of United States trials.
Barqawi A; Thompson IM; Crawford ED
J Urol; 2004 Feb; 171(2 Pt 2):S5-8; discussion S9. PubMed ID: 14713745
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents.
Nelson WG; Wilding G
Urology; 2001 Apr; 57(4 Suppl 1):56-63. PubMed ID: 11295596
[TBL] [Abstract][Full Text] [Related]
39. Androgens and prevention of prostate cancer.
Sarvis JA; Thompson IM
Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):271-7. PubMed ID: 18438176
[TBL] [Abstract][Full Text] [Related]
40. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.
Cui K; Li X; Du Y; Tang X; Arai S; Geng Y; Xi Y; Xu H; Zhou Y; Ma W; Zhang T
Oncotarget; 2017 May; 8(22):36674-36684. PubMed ID: 28415774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
